PHILADELPHIA, Pa, February 22, 2021 – PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced that Christopher M. Cashman, former chairman and chief executive officer of Marinus Pharmaceuticals, Inc., has been elected to PolyCore’s board of directors, effective February 19, 2021.
“We are thrilled to welcome Chris to our board of directors,” said Jim Harris, chairman of the board of PolyCore Therapeutics. “Chris brings over 30 years of executive leadership experience in leading life sciences companies, including his experience in neuropsychiatric therapeutics, and we look forward to the valuable perspective his strategic leadership will add to PolyCore.”
Mr. Cashman brings to the PolyCore board extensive experience in building and leading companies from startup and early financing through IPO, late-stage development, commercialization and merger/acquisition.
Prior to his role at Marinus, Mr. Cashman served as president and chief executive officer of Protez Pharmaceuticals, a company specializing in the development of hospital antibiotics to treat drug resistant infections that he co-founded in 2003. Protez was acquired by Novartis in 2008. Mr. Cashman also serves as chairman of the board at MBF Therapeutics and is a director of Noble Biomaterials. He also serves on the board of Life Sciences Pennsylvania and the University City Science Center.
“Chris will provide valuable insight as we continue to advance our lead compound, PCT-3012 for Parkinson’s Disease,” said Kelly Beck, Chief Executive Officer of PolyCore. “Additionally, his experience in financing and capital structures will be beneficial as we continue to grow the company.”
“This is an exciting time to join PolyCore’s board of directors. PolyCore’s lead compound holds great promise and I look forward to working with the team to support the advancement of their portfolio,” said Mr. Cashman.
About PolyCore Therapeutics
PolyCore Therapeutics LLC is a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders. PolyCore is current conducting preclinical studies for its lead compound, PCT-3012, a novel small molecule for treatment of Parkinson’s motor symptoms and dyskinesia in patients with early- to mid-stage Parkinson’s Disease. For more information, visit www.polycoretherapeutics.com.